Stoke Therapeutics (STOK)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
At a market value of $1.5B, Stoke Therapeutics's free cash flow of $45M (fiscal 2025) would need to grow about 11% a year for the stock to be worth today's price.
Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from Stoke Therapeutics's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.
Fundamental grade
Five factors scored 1 to 9 from STOK's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from Stoke Therapeutics's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | $12M | $9M | $37M | $184M |
| Net income | -$86M | -$101M | -$105M | -$89M | -$7M |
| Free cash flow | -$68M | -$36M | -$83M | -$87M | $45M |
| EPS (diluted) | -$2.34 | -$2.60 | -$2.38 | -$1.65 | -$0.12 |
| Operating margin | — | -841.2% | -1307.2% | -277.3% | -11.2% |
Superinvestors who own STOK
From each investor's latest 13F filing (what a 13F shows). 1 of the investors we track hold it.
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| Cliff Asness AQR Capital Management |
Trimmed | $865,411 | 0.0% | Q2 2026 |
Insider buying
Open-market purchases by Stoke Therapeutics's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when STOK trades at or below it.
New accounts get 7 days of Pro, price alerts included. No card needed.
In the full deep dive
Questions
What growth does Stoke Therapeutics's stock price imply?
At a market value of $1.5B, Stoke Therapeutics would need its free cash flow to grow about 11% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price.
Are Stoke Therapeutics insiders buying the stock?
No open-market insider purchases of STOK in the last 12 months, according to SEC Form 4 filings.
Which superinvestors own Stoke Therapeutics?
1 of the superinvestors Investingly tracks hold STOK in their latest 13F, including Cliff Asness.
Companies like Stoke Therapeutics
All Healthcare stocks · Biotechnology stocks · Stock lists
Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.